Fresenius Dialysis Lawsuit Funding for Granuflo Plaintiffs

Katarina Siegfeld | October 6th, 2014

Fresenius Medical Care logoAs the number of GranuFlo and NaturaLyte heart attack lawsuits consolidated as part of federal litigation now exceeds 2,000, some plaintiffs may be in need of Fresenius dialysis lawsuit funding to pursue the compensation for their injuries and losses.

By mid September, there were 2,089 cases concerning the dialysis products pending in the federal court located in Worcester, Massachusetts under U.S. District Judge Douglas P. Woodlock.  The cases are similar in that they share allegations that the defendant, Fresenius Medical Care, failed to warn patients and doctors about the possibility that its products could lead to heart attacks in dialysis patients under certain circumstances.

Judge Woodlock is presiding over a multidistrict litigation (MDL) in which all the cases (and any more that join in the future) will share a pre-trial discovery process before preliminary cases (known as “bellwether” cases) are held to test juries’ reactions and set the precedent for either further trials or the establishment of large scale settlements.  The first bellwether case will not be heard until January of 2016.

In the intervening period, all current and potential plaintiffs should be aware that lawsuit funding is available to assist them financially.

Fresenius dialysis lawsuit funding may be necessary

Plaintiffs who have been affected by the GranuFlo and NaturaLyte products were already receiving dialysis treatment, with all of the medical and other expenses that such treatment entails.  To suffer a heart attack due to the products’ defects adds an additional blow to patients or their families:  more medical expenses, loss of income or earning potential, the sudden absence of a family breadwinner in the case of death, funeral expenses, and more may await such victims or their loved one.

Attorneys for the plaintiffs believe that they have a good case against the defendant, citing a memo circulated within the company in 2011 that described a 6-fold increase in heart-related deaths in clinics using their products.  This increase was due to the output of bicarbonate as a byproduct during the dialysis process when NaturaLyte and GranuFlo were used and a failure to compensate for this byproduct by doctors, who were never informed of the danger by the company.  It was only after the FDA received a leaked copy of the memo in 2012 that a recall was issued.

A jury award or settlement may eventually cover unfortunate financial losses suffered by the company’s failure to warn.  But the legal process will be a long and complicated one and not all plaintiffs have the resources to make it through this period without help.

LawStreet Capital offers Fresenius dialysis legal loans

LawStreet Capital is a resource for plaintiffs who will need such assistance in the next few years.  We can offer you a Fresenius dialysis legal loan to help you through.  Don’t be put off or confused by the term legal “loan”:  what we actually offer is more like a cash advance that does not have to be repaid if your case is not successful.  A “pre-settlement loan” is available as you await the resolution of your case and a “post-settlement loan” is also available after a settlement is reached but before it is dispersed.

At a time when you have pressing medical and personal concerns which require your attention, there is no need to suffer additional stress over financial concerns.  Call us a 1-866-FUND-662 to set up a free, no-obligation consultation with one of our representatives to answer any questions that you may have about available funding options.